Fresenius is expanding its biosimilar manufacturing strategy through a WuXi Biologics partnership, gaining access to 37 candidates and strengthening its long-term biopharma ambitions.
RPG Life Sciences' 500 crore acquisition bet could redefine its API business, expand manufacturing capacity and accelerate export growth.
Sun Pharma’s Q2 profit falls as acquisition costs rise, despite revenue growth and stronger operating performance across key business segments.
Omron's Chennai factory puts medical device localization in focus as India seeks domestic production, component sourcing and a larger role in global healthcare supply chains.
World markets drive Strides Pharma’s 17% rise this quarter as the company’s non-US markets generate more revenue than its traditional American business for the first time.
The London Biotechnology Show 2026 will return to ExCeL London on 18–19 November, bringing together biotechnology and pharmaceutical companies, researchers, healthcare professionals, investors, policymakers and technology providers
GSK share price falls despite a third quarter earnings beat as weaker vaccine sales, Shingrix and Arexvy disappoint investors.
Cipla’s respiratory muscle drives US growth, but can its commercial network deliver success with a Keytruda biosimilar in oncology?
Cipla’s Rs 423 crore R&D investment signals a long-term growth bet despite a 35% profit decline and weaker US sales.
Eris Lifesciences targets semaglutide market expansion to Rs 80-90 crore monthly by next year, driven by rising demand for diabetes therapies.
.jpg)
, CDSCO.jpg)
